ADMA — ADMA Biologics Inc

Is ADMA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of October 3, 2026

ADMA Biologics Inc (ADMA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $9.72. The rating moved from Neutral to Overbought on October 1, 2026.

See all overbought Healthcare stocks →

AI analysis

ADMA Biologics Inc (ADMA) sits in a defensive niche with recurring revenue from plasma‑derived immunoglobulins and a manufacturing footprint that can support specialty growth; however, the company remains sensitive to payer reimbursement shifts, plasma supply and manufacturing execution, and small‑cap funding dynamics. Near‑term market tone is cautious, so meaningful share appreciation likely requires clear clinical, regulatory, or contract wins or visible margin expansion. Key upside catalysts include new indications, durable commercial uptake, improved manufacturing utilization and favorable contract wins with payers or distributors. Main downside scenarios involve reimbursement headwinds, supply or manufacturing interruptions, and dilutive capital raises that would pressure per‑share value.

Key factors

  • Established plasma‑derived immunoglobulin product portfolio addressing immunodeficiency and related indications; recurring revenue from replacement therapies provides a baseline cash flow.
  • Manufacturing and plasma supply capabilities are strategic advantages but require steady scale and capital investment to support growth and margin improvement.
  • Recent specialty biologics tailwinds (positive late‑stage data in the sector) support favorable investor appetite for differentiated rare‑disease and specialty therapies.
  • Exposure to U.S. reimbursement dynamics (Medicare/IRA and PBM negotiations) creates pricing and access uncertainty for higher‑cost therapies.
  • Risk‑off macro sentiment and light volumes reduce conviction for near‑term directional moves absent clinical, regulatory, or contract catalysts.
  • Small‑cap liquidity and historical operating losses increase sensitivity to capital markets/dilution risk if additional funding is required.

Risks

  • Medicare drug‑price negotiation and broader payer cost containment actions could pressure net pricing and formulary access for immunoglobulin products.
  • Plasma supply constraints, collection disruptions, or manufacturing setbacks that limit ability to fulfill demand and harm revenue/profitability.
  • Regulatory risks including facility inspections, product recalls, or approval delays for new indications or formulations.
  • Need for external financing to fund growth or refinance debt, leading to dilution or higher financing costs if market windows are unfavourable.
  • Competitive pressure from alternative therapies, newer biologics, or biosimilars that erode market share or pricing power.
  • Macro risk‑off environment that suppresses IPOs, secondary raises and investor appetite for smaller specialty pharma names, increasing volatility.
  • Operational execution risk around commercial expansion, contracting with large payers/MA plans, and scaling specialty distribution.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ADMA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.